Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS

Health Care Cost by Tax Credits

From the Reuters news article:

The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.

Read more at the link:

About Author: GHCAN Admin

Comments are closed.